Rony R Sayegh1, Yinxi Yu2, John T Farrar3, Eric J Kuklinski4, Roni M Shtein5, Penny A Asbell6, Maureen G Maguire2. 1. Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine, Cole Eye Institute, Cleveland, OH. 2. Departments of Ophthalmology; and. 3. Neurology, University of Pennsylvania, Philadelphia, PA. 4. Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY. 5. Department of Ophthalmology, University of Michigan, Ann Arbor, MI; and. 6. Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN.
Abstract
PURPOSE: To assess the association of severity of ocular discomfort with measures of quality of life among patients with moderate to severe dry eye disease (DED). METHODS: This is a prospective, observational, cohort study within a randomized clinical trial. Patients (N = 535) in the Dry Eye Assessment and Management study with moderate to severe DED completed the Ocular Surface Disease Index on DED symptoms, the SF-36 on quality of life, and the Brief Ocular Discomfort Inventory questionnaire and had a comprehensive ophthalmic assessment by a study-certified clinician. The ocular discomfort on average over the past week was scored on an 11-point scale (0 for no discomfort and 10 for discomfort as bad as you can imagine). RESULTS: The average ocular discomfort scores for patients ranged from 0 to 10, with a mean of 4.28. Discomfort scores did not vary with demographic characteristics, signs of DED, self-reported depression, or self-reported nonocular pain conditions. Ocular discomfort scores did correlate moderately to strongly with total Ocular Surface Disease Index scores (Spearman correlation coefficient, rs, 0.47-0.67) and with measures of interference with activities of daily living [general activity level, mood, walking ability, ability for normal work, relations with other people, sleep, and enjoyment of life (rs = 0.39-0.65)]. CONCLUSIONS: Among patients in the Dry Eye Assessment and Management study, worse ocular discomfort was associated with worse overall DED symptoms and interfered to a greater degree with activities of daily living. Ocular discomfort is an important part of the assessment of patients with DED.
PURPOSE: To assess the association of severity of ocular discomfort with measures of quality of life among patients with moderate to severe dry eye disease (DED). METHODS: This is a prospective, observational, cohort study within a randomized clinical trial. Patients (N = 535) in the Dry Eye Assessment and Management study with moderate to severe DED completed the Ocular Surface Disease Index on DED symptoms, the SF-36 on quality of life, and the Brief Ocular Discomfort Inventory questionnaire and had a comprehensive ophthalmic assessment by a study-certified clinician. The ocular discomfort on average over the past week was scored on an 11-point scale (0 for no discomfort and 10 for discomfort as bad as you can imagine). RESULTS: The average ocular discomfort scores for patients ranged from 0 to 10, with a mean of 4.28. Discomfort scores did not vary with demographic characteristics, signs of DED, self-reported depression, or self-reported nonocular pain conditions. Ocular discomfort scores did correlate moderately to strongly with total Ocular Surface Disease Index scores (Spearman correlation coefficient, rs, 0.47-0.67) and with measures of interference with activities of daily living [general activity level, mood, walking ability, ability for normal work, relations with other people, sleep, and enjoyment of life (rs = 0.39-0.65)]. CONCLUSIONS: Among patients in the Dry Eye Assessment and Management study, worse ocular discomfort was associated with worse overall DED symptoms and interfered to a greater degree with activities of daily living. Ocular discomfort is an important part of the assessment of patients with DED.
Authors: Penny A Asbell; Maureen G Maguire; Maxwell Pistilli; Gui-shuang Ying; Loretta B Szczotka-Flynn; David R Hardten; Meng C Lin; Roni M Shtein Journal: N Engl J Med Date: 2018-04-13 Impact factor: 91.245
Authors: Erin S Ong; Elizabeth R Felix; Roy C Levitt; William J Feuer; Constantine D Sarantopoulos; Anat Galor Journal: Br J Ophthalmol Date: 2017-08-18 Impact factor: 4.638
Authors: Anat Galor; Elizabeth R Felix; William Feuer; Nabeel Shalabi; Eden R Martin; Todd P Margolis; Constantine D Sarantopoulos; Roy C Levitt Journal: Br J Ophthalmol Date: 2015-02-20 Impact factor: 4.638